Hosted on MSN5d
Denali Starts Dosing in Phase II Parkinson's Disease StudyDenali Therapeutics Inc. DNLI initiated dosing in a global mid-stage study, BEACON, on BIIB122 (DNL151). BIIB122, an ...
Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...
Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...
BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.
BEACON study is a phase IIa trial evaluating the company's investigational drug BIIB122 (DNL151), a selective LRRK2 inhibitor, for Parkinson's disease linked to LRRK2 mutations (LRRK2-PD).
BIIB122 is also being investigated in the ongoing global Phase 2b LUMA study in participants with early-stage Parkinson’s disease with or without a LRRK2 mutation, in collaboration with Biogen.
The Phase 2a study is intended to evaluate safety and biomarkers associated with oral daily dosing of BIIB122 in approximately 50 participants with Parkinson’s disease and LRRK2 pathogenic ...
Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback